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Amyotrophic lateral sclerosis (ALS) is the most common and most aggressive form of adult
motor neuron (MN) degeneration. The cause of the disease is still unknown, but some
protein mutations have been linked to the pathological process. Loss of upper and lower
MNs results in progressive muscle paralysis and ultimately death due to respiratory failure.
Although initially thought to derive from the selective loss of MNs, the pathogenic concept
of non-cell-autonomous disease has come to the forefront for the contribution of glial cells
in ALS, in particular microglia. Recent studies suggest that microglia may have a protective
effect on MN in an early stage. Conversely, activated microglia contribute and enhanceMN
death by secreting neurotoxic factors, and impaired microglial function at the end-stage
may instead accelerate disease progression. However, the nature of microglial–neuronal
interactions that lead to MN degeneration remains elusive. We review the contribution of
the neurodegenerative network inALS pathology, with a special focus on each glial cell type
from data obtained in the transgenic SOD1G93A rodents, the most widely used model.
We further discuss the diverse roles of neuroinﬂammation and microglia phenotypes in
the modulation of ALS pathology. We provide information on the processes associated
with dysfunctional cell–cell communication and summarize ﬁndings on pathological cross-
talk between neurons and astroglia, and neurons and microglia, as well as on the spread
of pathogenic factors. We also highlight the relevance of neurovascular disruption and
exosome trafﬁcking to ALS pathology. The harmful and beneﬁcial inﬂuences of NG2 cells,
oligodendrocytes and Schwann cells will be discussed as well. Insights into the complex
intercellular perturbations underlying ALS, including target identiﬁcation, will enhance our
efforts to develop effective therapeutic approaches for preventing or reversing symptomatic
progression of this devastating disease.
Keywords: amyotrophic lateral sclerosis, microglia activation phenotypes, motor neuron, neuroinflammation,
neurodegeneration, pathological cell–cell communication, SOD1G93A transgenic mouse/rat
INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is a non-cell-autonomous
disease targetingmotor neurons (MNs) and neighboring glia, with
microgliosis directly contributing to neurodegeneration (Beers
et al., 2006; Lobsiger and Cleveland, 2007; Yamanaka et al., 2008a).
Indeed, the neurodegenerative process in ALS was shown to be
accompanied by a sustained inﬂammation in the brain and spinal
cord (SC) (Bowerman et al., 2013). Recently, microglia were sug-
gested to be implicated in ALS initiation (Gerber et al., 2012), as
well as to lose their surveillance capacity by switching from an acti-
vated to a neurodegenerative phenotype as the disease progresses
(Weydt et al., 2004; Dibaj et al., 2011). Therefore, a better thera-
peutic strategy should envisage the recovery of healthy microglia
from those transformed cells near the most affected MNs in the
SC. In such way we may preserve the passage of toxic mediators to
environmental cells, and maintain the homeostatic conditions.
For the vast majority of patients with ALS, the etiology of
the disorder is unknown. Actually, only some ALS cases (less
than 10%) have been linked to mutations in a number of
genes, including in the enzyme Cu, Zn superoxide dismutase
1 (SOD1), TAR DNA binding protein (TDP-43), fused in sar-
coma (FUS), optineurin (OPTN), valosin-containing protein
(VCP), ubiquilin 2 (UBQLN2), proﬁlin 1 (PFN1), and chromo-
some 9 open reading frame 72 (C9ORF72) repeat expansions
(Tovar et al., 2009a; DeJesus-Hernandez et al., 2011; Ince et al.,
2011; Renton et al., 2011, 2014; Bertolin et al., 2013). Interest-
ingly, both the non-genetic and the genetic forms of ALS are
suggested to have common pathogenic mechanisms (Lilo et al.,
2013), as well as similar clinical courses and dysfunctional fea-
tures, such as the abnormal accumulation of neuroﬁlaments in
degenerating MNs (Julien, 2001). Actually, cytoplasmic aggre-
gation of nuclear TDP-43 and FUS in the degenerating neu-
rons and glia of ALS patients, and release of the accumulated
cytoplasmic mutant SOD1 (mSOD1) to the extracellular space
that can be taken up by other cells, are common features (Li
et al., 2013; Ogawa and Furukawa, 2014). The identiﬁcation
of C9ORF72 repeat expansions in patients with ALS but with-
out a family history of ALS challenged the division between
genetic (familial) and non-genetic (sporadic) cases (Turner et al.,
2013). As indicated by Kiernan (2014), the true substrate of
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ALS may reside in a pathogenic signature of nuclear protein
mishandling.
There are several in vitro and in vivo models of MN
degeneration. In vitro experimental models include SC cultures,
NSC-34 cell line expressing the mSOD1 and organotypic cultures,
while the axotomy-induced MN death, the naturally occurring
ALS models, and the transgenic models are the most commonly
used in vivo models (Elliott, 1999; Tovar et al., 2009a). Among
the various transgenic models used in the study of ALS patho-
genesis (Weydt et al., 2004; Kato, 2008), the transgenic rodent
overexpressing mSOD1, in particular the SOD1G93A strain, is the
most utilized and characterized. Transgenic mice containing other
mSOD1 genes (G85R, G37R, D90A, or G93A missense mutations
or truncated SOD1) and the related mutant (G86R) mouse have
also shown progressive neurodegeneration of the motor system
and resemblance to ALS (for review, see Van Den Bosch, 2011).
Distinctive injurious effects between SOD1G93A and SOD1H46R
on two different genetic backgrounds were recently recognized
(Pan et al., 2012). Additionally developed models are based on
TDP-43 (Wegorzewska et al., 2009; Liu et al., 2013; Yang et al.,
2014) and FUSmutations (Verbeeck et al., 2012), but none of these
models is currently used to study the pathogenesis of ALS and to
test new drugs. Thus, the human mSOD1 murine model is the
most widely used in the evaluation of the involved molecular tar-
gets, biomarkers and novel drugs/treatments for ALS. Apart from
developing loss of MNs and symptoms that resemble human ALS
by mSOD1, the model evidences molecular links between genetic
and non-genetic cases of ALS (Andjus et al., 2009; Synofzik et al.,
2010). To note, that non-genetic perturbations of the wild-type
(wt) SOD1proteinmay lead to SOD1misfoldingwith a conforma-
tion much similar to genetic SOD1 variants (Cereda et al., 2006).
Therefore, in this review we will summarize the most recent devel-
opments obtained in the SOD1G93A transgenic model to give
consistency and cohesion between the data disclosed, and because
we admit that common factors and pathways are shared in both
genetic and non-genetic derived ALS cases, in particular changes
in microglia performance and in neuron–glia communication.
It was initially considered that the selective death of MNs
expressing the mutant protein was the player in the disease
onset. However, non-cell-autonomous processes associated with
mSOD1 in glial cells are believed to be implicated not only in
disease progression and extent, but also to be related with the
onset and early stage of the disease, thus underlying MN dys-
function and loss. Indeed, healthy glia evidenced to delay the
progression of the disease (Boillée et al., 2006b; Yamanaka et al.,
2008b) and the replacement of mSOD1 microglia by wt microglia
slowed disease progression and prolonged mice survival (Lee et al.,
2012). This ﬁnding is in line with previous studies showing that
mSOD1 in microglia leads to the disease (Clement et al., 2003)
and that the reduction of the mutant levels in the cells slows ALS
progression (Boillée et al., 2006b). Indeed, damage to MNs by
neighboring cells expressing mSOD1 seems to be required for MN
degeneration (Pramatarova et al., 2001; Lino et al.,2002). Accumu-
lating knowledge on the active participation of different microglia
phenotypes in ALS was recently obtained when microglia were
isolated from SOD1G93A rats at presymptomatic, symptom onset
and end-stage periods (Nikodemova et al., 2013). Microglia were
shown to be regionally different and to evidence a heterogene-
ity of phenotypes with the disease progression. Thus, it will
be interesting to investigate the inﬂuence of changes caused by
aging in the performance of the mutated microglia, namely on
the interconnectivity with neurons and other glial cells. More-
over, our preliminary data indicate a decreased phagocytic and
migration ability of healthy microglia by the soluble factors
(SFs) released by NSC-34 cells expressing mSOD1, thus caus-
ing the loss of important microglia properties (Cunha, 2012). In
addition, when this microglia was co-cultured with the mMNs
we observed a reduction of the activation of matrix metal-
loproteinases (MMP)-2 and -9 in the extracellular media after
cultivation for 4 days in vitro (DIV) (Barbosa, 2013), evidencing
the beneﬁcial effect of the healthy microglia in decreasing mMN
stress.
Finally, we provide an outlook on the extent to which a diverse
cellular environment may determine different pathological win-
dows along disease progression opening new opportunities to
explore distinct therapeutic approaches to either trigger a less
reactive microglia phenotype at the early-onset, or a recovery
of microglia dynamics at late-stage ALS. It will be also summa-
rized recent advances in regenerative medicine technologies with
potential to reverse or halt ALS progression by slowing MN death.
NEURODEGENERATIVE NETWORKING IN ALS
Neuronal homeostasis and survival were shown to be compro-
mised in ALS due to multiple aberrant biological processes and
to deregulated communication between neurons and glial cells
in the brain and in SC by the disease. ALS, once considered
a MN disease, is now known to have multiple inﬂuences and
regarded as a multi-cellular/multi-systemic disease (Nardo et al.,
2011). In fact, MN death seems to be driven by a convergence of
damaging mechanisms, including glial cell pathology and inﬂam-
matory conditions, such as microglial activation or the invasion
of lymphocytes, and calcium dysregulation (Grosskreutz et al.,
2010; Beers et al., 2011b). It can be also determined by exci-
totoxicity due to the selective loss of the astrocytic glutamate
transporter GLT-1, and consequent accumulation of extracellu-
lar glutamate (Rothstein, 2009). Our late results with astrocytes
isolated from SOD1G93A mice and cultivated for 13 DIV suggest
that both GLT-1 and glutamate aspartate transporter (GLAST) are
compromised (personal communication) and corroborate other
ﬁndings indicating that expression of such transporters are less
potently activated by lipopolysaccharide (LPS) in astrocytes from
the mSOD1 model than in those from the wt mice (Benkler et al.,
2013). Other contributing processes include from neurovascular
changes and compromised barriers of the central nervous sys-
tem (CNS), to dysfunctional communication between neurons,
abnormal neuron–glia interactions, and microglia and astroglia
loss-of-function.
In fact, for the optimal functioning of the CNS, i.e., brain
and SC, accounts the constant immune surveillance promoted
by cells such as microglia, and the blood–brain barrier (BBB),
the blood–SC barrier (BSCB), and the blood–cerebrospinal ﬂuid
(BCSF) barrier that uniquely shield CNS from potential mediators
of infection and damage. Recently, brain pericytes, as important
components of the neurovascular unit in the CNS, have shown to
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have pleiotropic and regulatory activities in brain vessel function
and homeostasis, blood ﬂow and barrier function (Lange et al.,
2012). Astrocytes also participate in maintaining homeostasis and
supporting neuronal function. In addition to microglia, neu-
rons have lately been indicated to intervene in immune responses
through control of T cells inﬁltration into the CNS and glial
cell immunoreactivity (Czirr and Wyss-Coray, 2012; Tian et al.,
2012; Liblau et al., 2013). This integrative network sustains ionic,
energetic, and redox homeostasis for proper function.
Moreover, ALS progression was suggested to involve cell-to-cell
transmission of mSOD1 aggregates involving MNs, microglia and
astrocytes, similarly to prion disease (Chia et al., 2010; Munch
et al., 2011). Interestingly, the transcellular spread of SOD1
aggregates evidenced to not require cell-to-cell contacts but to
depend from their fragmentation and extracellular release. How-
ever, additional studies should demonstrate that similar ﬁndings
also occur in vivo. Intriguingly, while extracellular mSOD1G93A
has shown to not have direct toxic effects on MNs, it mor-
phologically and functionally activates microglia, supporting the
non-cell-autonomous nature of MN toxicity in ALS (Zhao et al.,
2010). Indeed, it was shown that this extracellular mSOD1
can be endocytosed into microglia, determining the activa-
tion of caspase-1 and the up-regulation of interleukin (IL)-1β
(Zhao et al., 2013).
Another interesting concept is that astrocyte and microglia
activation, which is regulated by a variety of signaling pathways,
should not be considered merely as pernicious for CNS home-
ostasis, once it promotes metabolic support, wound healing and
repair. In fact, the production of cytokines and chemokines initiate
and coordinate diverse cellular and intercellular actions. Although
neurons and glial cells of the CNS express receptors for cytokines
and chemokines, the biological consequence of receptor activation
is not fully understood. In contrast, it must be considered as part
of the pathological processes the excessive or deregulated signal-
ing pathways leading to microglia and astrocyte abnormalities that
culminate in abnormal CNS function.
Thus, progressive neurodegeneration of MNs in ALS may
result from a combination of intrinsic MN vulnerability to
mSOD1 aggregates and of non-cell-autonomous toxicity derived
from neighboring cells (Tables 1 and 2). Therefore, pathologi-
cal changes in ALS indicate a broken homeostasis in the CNS.
We will focus on how CNS homeostasis is lost in ALS and in
what way BBB and neural networks dysregulation contribute to
neurodegeneration in ALS.
MOTOR NEURON DYSFUNCTION
A certain number of cases are linked to mutations in SOD1 and
candidate mechanisms are the formation of protein aggregates
and pro-oxidant effects. Therefore, most of the experiments are
generally conducted in the MN-like hybridoma cell line NSC-34
expressing human mSOD1 (hSOD1G93A) (Tovar et al., 2009a) or
in the transgenic mice generated by Gurney et al. (1994) that also
over-express hSOD1G93A (Riboldi et al., 2011).
SOD1 aggregates are observed in both genetic and non-genetic
ALS cases, but their contribution to MN toxicity remains to
be established, although deregulation of Golgi, endoplasmic
reticulum (ER), and mitochondria, together with axonal transport
defects have been indicated (for review, see Boillée et al., 2006a;
Rothstein, 2009). Interestingly, when working with the NSC-
34/hSOD1G93A cells we found that one of the most sensitive
indicators of SOD1 accumulation and neuronal dysfunction was
the elevation of MMP-9, but not of MMP-2 that remained
unchanged (Cunha, 2012; Vaz et al., 2014). Elevation of the MMP-
9 levels was previously observed in the SC of ALS mice from
pre-symptomatic phase, predominantly in MNs but also in glia
(Soon et al., 2010). These authors suggest that circulating MMP-9
is associated with the disease onset and is mainly derived from
degenerating SC MNs and circulating cells. Its inhibition was
shown to enhance animal survival in more than 30% (for review,
see Riboldi et al., 2011). It was also found in the CNS, muscles,
plasma, and skin of patients. Major inducers are reactive oxy-
gen species (ROS) and cytokines released by microglia. Once
MMP-9 is indicated to promote the regeneration of the injured
neuron, it may be hypothesized that its increase results from a MN
response to the pathology. However, it was recently claimed that
MMP-9 is indeed a determinant of the selective neurodegenera-
tion (Kaplan et al., 2014). The Authors demonstrated that MMP-9
is only expressed by the selectively vulnerable fast MNs and can
originate ER stress and axonal dye-back. This ﬁnding provides
a basis for considering MMP-9 as a candidate target for novel
therapeutic approaches to ALS.
Oxidative damage at the level of proteins, lipids, and DNA was
also observed in the transgenic hSOD1 mice models (Liu et al.,
1999; Casoni et al., 2005; Poon et al., 2005; Barbosa, 2013) where
mSOD1 revealed to be the most severely oxidized protein mouse
(Andrus et al., 1998). Also accounting to MN disturbance is the
failure of the Keap1/Nrf2/ARE system in regulating stress proteins,
as evidenced along disease progression in MNs from the SC of
hSOD1G93A mice (Mimoto et al., 2012). In addition, failure in
MN autophagy was revealed as critical in the pathogenesis and
progression of ALS (for review, see Pasquali et al., 2009; Chen
et al., 2012; Otomo et al., 2012).
Currently, there is no cure for the ALS disease, although
Riluzole, the only drug approved by the U.S. Food and Drug
Administration (FDA), was shown to prolong median patient sur-
vival by 2–3 months and to be more effective when administered
at an early stage of the disease (Zoccolella et al., 2007; Lee et al.,
2013a). More potent therapeutic strategies may derive from better
target identiﬁcation and clariﬁcation of signalingmechanisms able
to be modulated and from the use of cell-based therapies, such as
the administration of mononuclear cells from human umbilical
cord blood (Garbuzova-Davis et al., 2012) and of mesenchymal
stromal (stem) cells (Uccelli et al., 2012), as referred to in Section
“Challenges to Nerve Regeneration in ALS.” Bellow we introduce
what is known about the most prominent MN membrane pro-
teins and SFs suggested to be implicated in ALS pathology, but still
deserving to be more explored.
Perturbations in glutamate handling
Glutamate excitotoxicity is one primarily cause of neuronal death
by necrosis and apoptosis and a critical player in ALS onset
and progression. Indeed the blockade of the glutamate trans-
porter in a SC organotypic slice model from SOD1G93A rats has
shown to result in an increased survival of MNs (Yin and Weiss,
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Table 1 | Functional alterations of motor neurons (MNs) in amyotrophic lateral sclerosis (ALS): candidate molecular targets.
Changes in MN signaling by ALS ALS stages Reference
Elevation of matrix metalloproteinase (MMP)-9 Pre-symptomatic phase Soon et al. (2010), Kaplan et al. (2014)
Impaired antioxidative Keap1/Nrf2/ARE system Along disease progression Mimoto et al. (2012)
Oxidative and nitrosative stress Early phase Drechsel et al. (2012)
Glutamate excitotoxicity Onset and progression Spalloni et al. (2013)
Release of ATP Along disease progression Glass et al. (2010)
Protein misfolding, aggregation, and accumulation Onset and progression Julien (2001), Li et al. (2013)
Changes in fractalkine (CX3CL1), CD200, and CCL21 Not clariﬁed –
Decreased high-mobility group box protein 1 (HMGB1) cellular expression Advanced phase Lo Coco et al. (2007), Fang et al. (2012)
Release of neuregulin-1 (NRG1) Along disease progression Song et al. (2012)
Up-regulation of major histocompatibility complex (MHC) class I and
β2-microglobulin mRNAs
Along disease progression Staats et al. (2013)
2012). Glutamate, by activating the glutamatergic ionotropic
receptor N-methyl-D-aspartate (NMDAR), triggers the inﬂux of
Ca2+ into neurons, increasing its intracellular levels (for review,
see Spalloni et al., 2013). In these conditions, changes in mito-
chondria dynamic properties are produced leading to excessive
oxidative phosphorylation and increased generation of ROS and
reactive nitrogen species (RNS) that culminate in apoptosis. In
parallel, the NMDAR excitotoxicity also results in the release
of Ca2+ from the ER. In addition, it was shown that ER stress
resulting from the accumulation of aggregated mSOD1 and dys-
function of the unfolded protein response (UPR) activation
contributes to the apoptotic signaling cascade in ALS (for review,
see Sofroniew, 2009).
Besides the synaptic glutamate pool directly implicated in the
excitatory neurotransmission it has been lately additionally con-
sidered the extra-synaptic glutamate pool that inﬂuences cell
communication. This pool, mainly derived from astrocyte and
microglia release, is greatly increased by pathological stimuli
(for review, see Rodriguez et al., 2013). Besides being impli-
cated in many physiological conditions glutamate contribution
to neuron–glia alterations of homeostasis and to the pathophys-
iology of neurodegenerative diseases, such as ALS, needs to be
explored in the near future, due to controversial results. In
fact, although linkage between glutamate and neuroinﬂamma-
tion was suggested to have a role in potentiating MN death
in a model mimicking ALS disease (Tolosa et al., 2011), other
Authors have demonstrated that glutamate by itself was not able
to induce MN damage in ALS (Tovar et al., 2009b). Indeed,
it has been questioned the involvement of glutamate in ALS-
induced MN death (Le Verche et al., 2011) and the cytotoxicity
of the cerebrospinal ﬂuid (CSF) from patients with ALS evi-
denced to not be related to glutamate (Gomez-Pinedo et al.,
2013).
Membrane-bound and soluble fractalkine (CX3CL1)
Fractalkine (FKN) mRNA is dominantly expressed in neuronal
cells, particularly in those at the cortex, hippocampus, caudate
putamen, thalamus, and olfactory bulb (Harrison et al., 1998).
FKN mRNA was also detected in unstimulated astrocytes (more)
and microglia (less) (Mizuno et al., 2003). Interestingly, FKN
immunoreactivity and mRNA was observed also in the rat SC and
dorsal root ganglia neurons, but not in glia, and levels were not
enhanced by neuropathic conditions (Verge et al., 2004). FKN, or
CX3CL1, exists as amembrane-bound and soluble protein (sFKN)
allowing both adhesive and chemoattractive properties (Bazan
et al., 1997). In fact, the sFKN has potent chemoattractant activity,
recruiting CXCR1-expressing T cells, monocytes, and microglia to
the injuredneurons, aswell as in regulating the phagocytic capacity
of microglia (Cardona et al., 2006). sFKN was shown to increase
upon stimulation of glutamate (Chapman et al., 2000) and to
induce proliferation of human microglia (Hatori et al., 2002).
The constitutive expression of FKN and its receptor CX3CR1 in
microglia indicates its involvement in fundamental processes of
communication between neurons and microglia (Harrison et al.,
1998).
Under stimulation, such as an excitotoxic stimulus (Chap-
man et al., 2000), the membrane-bound form of FKN is rapidly
cleaved from cultured neurons and signiﬁcantly reduces neuronal
NMDA-induced apoptosis (Deiva et al., 2004). Indeed attenu-
ated glutamate-induced neuronal cell death was observed after
treatment of primary neuron–microglia co-cultures with sFKN
(Noda et al., 2011). Proteolytic cleavage of CX3CL1 is medi-
ated by action of metalloproteinase ADAM10 (Gough et al.,
2004), ADAM17 (Garton et al., 2001; Tsou et al., 2001), cathep-
sin S (CatS) (Clark et al., 2009), and MMP-2 (Bourd-Boittin
et al., 2009). Thus, cleavage of FKN may be prevented by
the inhibition of MMPs (Chapman et al., 2000). The source
of CatS is the activated microglial cells that upon stimula-
tion with LPS secrete sFKN to the extracellular media (Clark
et al., 2009). Similarly, stromal cell-derived factor-1 (SDF-1)
was indicated to stimulate the expression of ADAM17 and to
increase sFKN, while up-regulating FKN expression (Cook et al.,
2010).
In addition, FKN has a neuroprotective function by inhibiting
the nitric oxide (NO) production and the expression of inducible
NO synthase (iNOS) mRNA in activated microglia (Mizuno
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Table 2 | Glial impairment and deregulated glia–motor neuron (MN) interconnectivity in amyotrophic lateral sclerosis (ALS).
Mutant SOD1 cells Loss of supportive functions Contribution to ALS disease and MN
death
Reference
Astrocytes Deﬁcient astrocyte-speciﬁc glutamate
transporter EAAT2 (GLT-1)
Increase in the excitatory amino acid
glutamate
Valori et al. (2014)
Increased release of D-serine co-activator of the N -methyl-D-
aspartate (NMDA) receptors,
exacerbating glutamate toxicity on MNs
Valori et al. (2014)
Mitochondrial dysfunction Increased production of reactive
oxygen species (ROS)
Valori et al. (2014)
Release of interferon-γ and transforming
growth factor-β (TGF-β)
Increased neuroinﬂammation Valori et al. (2014)
Ubiquitin- and active
caspase-3-immunopositive
Degenerating astrocytes at the
pre-symptomatic stage when MNs
show axonal damage but are still alive
Valori et al. (2014)
Increased nerve growth factor (NGF) and
NO production
MN apoptosis Pehar et al. (2004)
Astrocytes (aberrant) Increased S100B and connexin-43 (Cx-43) Decreased MN survival Diaz-Amarilla et al. (2011)
Microglia (spinal cord – early stage) Recruitment of peripheral monocytes to
the CNS
Neuronal viability impairment Butovsky et al. (2012)
Microglia (spinal cord – end stage) Decreased expression of M1 and M2
markers
Decreased reactivity to stimuli Nikodemova et al. (2013)
Microglia (M2) – early stage High levels of anti-inﬂammatory cytokines
and neurotrophins
Enhancement of MN survival
(neuroprotection) at ALS early stage
Zhao et al. (2013)
Microglia (M1) – progressive stage Increased release of reactive oxygen
species (ROS), tumor necrosis factor-α
(TNF-α) and interleukin (IL)-1β
Toxicity to MN (death) in the late rapid
phase of ALS
Zhao et al. (2013)
Dystrophic microglia – end stage Decreased migration and phagocytosis by
aging (not yet conﬁrmed in ALS)
Neuronal degeneration by failure of the
senescent microglia response to stimuli
Luo and Chen (2012)
Oligodendrocytes Loss of the monocarboxylate transporter 1
(MCT1)
Decreased delivery of the metabolic
substrate lactate to MNs and axonal
sufferance
Philips et al. (2013)
NG2+ cells Increased proliferation rate and
degeneration of early-born
oligodendrocytes
Gray matter demyelination Kang et al. (2013)
Schwann cells Signs of distress at the asymptomatic
stage
Not known Valori et al. (2014)
et al., 2003). Interestingly, it was observed that FKN expression
was reduced in the brain of aged rats probably accounting for
the increase in microglial activation in such condition. In fact,
treatment with FKN has attenuated the age-related increase in
microglial activation (Lyons et al., 2009).
Taken together, FKN seems to have both intrinsic and anti-
inﬂammatory properties in the CNS and to act by interfering
with toxic microglial–neuron interactions (Suzuki et al., 2011).
Whether FKN may have a role in the development of ALS is still
not known.
High-mobility group box 1 protein
High-mobility group box 1 (HMGB1) protein, also known as
amphoterin, is an inﬂammatory factor that can be released
by astrocytes, microglia, and neurons, mainly when cells are
dying (for review, see Fang et al., 2012). HMGB1 has dual
activities depending on whether is alone (probably promoting
inﬂammation resolution and tissue regeneration) or forming
complexes with several proinﬂammatory mediators (potentiat-
ing inﬂammation and promoting innate immune cell activation)
(Bianchi, 2009). Nuclear HMGB1 regulates transcription of
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different sets of genes, including proinﬂammatory genes (Bianchi
and Manfredi, 2009; Park et al., 2009; Wong, 2013). Beneﬁcial
effects were observed in early CNS development but increased
levels of HMGB1 were shown to be correlated with apoptosis
and degeneration of neurons (Liu et al., 2009; Kawabata et al.,
2010). When neurons are injured, secretion of HMBG1 activates
microglia through receptor for advanced glycation end prod-
ucts (RAGE), Toll-like receptors (TLRs) 2, 4, and 9, as well as
Mac1 receptors (Kim et al., 2006a; Park et al., 2006; Neusch et al.,
2007), as depicted in Figure 1. Release of inﬂammatory medi-
ators by activated microglia further induces neuronal necrosis.
HMGB1 was indicated to decrease in neurons and to increase
in astrocytes with aging (Enokido et al., 2008). When expres-
sion and localization of HMBG1 was evaluated in the lumbar
SC of SOD1G93A transgenic mice, although intense reactivity
was found, no differences were obtained between controls and
the SOD1 mice (Lo Coco et al., 2007). However, since HMBG1
was identiﬁed in the cytoplasm of astrocytes and microglia
in SC samples from ALS patients (Casula et al., 2011) it may
trigger TLR signaling pathways. The ﬁnding was observed at
the late ALS phase and, thus, it will be important to follow
the TLR/RAGE cascade in animal models at different stages of
the disease. In contrast, a progressive reduction of HMGB1
immunopositive MNs was found at advanced stages and may
reﬂect the loss of MNs, reduced synthesis or enhanced released
of the cytokine (Lo Coco et al., 2007). Additional studies are
needed to investigate the causative hypothesis indicated for the
decreased HMGB1 immunoreactivity in MNs, inasmuch since it
can also have beneﬁcial effects on neuroregeneration (Fang et al.,
2012).
CCL21
CCL21 was shown to be implicated in signaling neuronal injury
to microglia through the receptor CXCR3. CCL21 expression
was demonstrated to increase in cortical neurons, in vitro, 2 h
after excitotoxic stimulus (de Jong et al., 2005). Intriguingly, these
authors demonstrated its location within vesicles that are trans-
ported along the neuronal process till presynaptic structures.
This chemokine is considered a chemotactic agent important
to drive microglia to the site of lesion. Astrocytes were also
indicated to have the receptor CXCR3, but unless high levels
of CCL21 are produced, no relevant changes can be observed,
indicating separate functions from microglia (van Weering et al.,
2010). CCL21 expression in CNS revealed to induce a mas-
sive brain inﬂammation, but not lymphocytic inﬁltration in
transgenic mice expressing the chemokine (Chen et al., 2002).
Interestingly, CCL21/CXCR3 signaling axis was never explored
in ALS.
CD200
The membrane glycoprotein CD200 is expressed in neurons and
in endothelial cells and its receptor CD200R is restricted to cells of
myeloid origin including macrophages and microglia. CD200 was
also evidenced to be induced by kainic acid in microglia (Yi et al.,
2012) and the authors have suggested that microglia are main-
tained in an activated state with autocrine signaling by interactions
FIGURE 1 | Neuron–microglia communication signaling pathways that
modulate microglia cell phenotypes.Toll-like receptor (TLR) signaling
contributes to classically activated microglia (M1) in response to
damage-associated molecular patterns (DAMPs). Following recognition of
DAMPs, TLRs activate downstream signaling cascades, activate nuclear
factor-κB (NF-κB) inducing the transcription of inﬂammatory mediators
associated with the M1-like microglial cell phenotype, such as the
proinﬂammatory cytokines interleukin (IL)-1β and tumor necrosis factor
(TNF)-α. The production of IL-1β can be achieved by the inﬂammasome
activation by DAMPs, leading to caspase-1 activation that orchestrates the
cleavage of pro-IL-1β to form active IL-1β, which leaves and binds to the IL-1
receptor, resulting in inﬂammation. Following activation, microglial cells
augment the immune response by releasing metalloproteinases (MMPs)
and increasing proinﬂammatory cytokines. High-mobility group box 1
(HMGB1) is an alarmin that signals cell damage in response to injury and
are associated to all the described signaling events. HMGB1 released by
activated microglia and damaged neurons concur for a vicious cycle
mediating chronic, progressive neurodegeneration associated with
neuroinﬂammation. HMGB1 can interact with receptors that include RAGE
(receptor for advanced glycation end products), TLR-2, TLR-4, Mac-1 also
known as CD11b, and possibly others. Alternatively activated microglia
(M2) functions include phagocytosis. Milk fat globule factor-E8 (MFG-E8)
produced by microglia recognizes phosphatidylserine (PS) as “eat me”
signals expressed on the surface of apoptotic neurons, triggering a
signaling cascade that stimulates phagocytosis to engulf the dying cell. In
order to maintain a quiescent microglia phenotype (M0) under steady-state
conditions, neurons suppress the activation of microglia through cell–cell
contact (CD200–CD200R) and by the release of the chemokine ligand 1
(CX3CL1) mediated by the cathepsin S that binds to its receptor CX3CR1
on microglia.
between microglial CD200 and CD200R, as well as in a surveil-
lant/quiescent state by interactions between neuronal CD200 and
microglial CD200R. In addition, they also demonstrated that IL-
4 leads to an increased expression of CD200 what may be the
mechanismdown-regulatingmicroglia activationwhenever IL-4 is
produced. In conclusion, deﬁcits in CD200–CD200R system exa-
cerbate microglia activation and the release of proinﬂammatory
cytokines (for review, see Jurgens and Johnson, 2012). Curiously,
multivariate analyses of gene expression have previously identiﬁed
alterations on the CD200R expression in presymptomatic SOD1
mice model (Chen et al., 2004). Thus, more studies on the role
of CD200/CD200R in ALS are needed to evaluate whether its
disruption is implicated in ALS.
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Neuregulins
Neuregulins have been showing to be implicated in a wide range
of neurological and psychiatric disorders including multiple scle-
rosis, schizophrenia, and AD. Neuregulin precursors are expressed
predominantly in cortical neurons, but also accumulate at the sur-
face of whitematter astrocytes. CSF neuregulin was found reduced
in ALS and increased in AD (Pankonin et al., 2009). Neuregulin-1
(NRG1) is a growth and differentiation factor that binds to erbB
receptors in microglia. NRG1–erbB signaling is activated after
peripheral nerve injury and contributes to microgliosis and neu-
ropathic pain (Calvo et al., 2010). Recently, it was suggested that
NRG1 released from damaged neurons and other cells in the SC
triggers microglial activation leading to progressive MN degener-
ation in ALS (Song et al., 2012). Indeed, it was observed that in
the early stage of ALS there was activation of NRG1 receptors on
microglia. Later on, a reduced membrane-bound NRG1 and an
increased mRNA expression were noticed in the SC. More studies
are, however, needed to sustain the NRG1 contribution to ALS
pathogenesis.
β2-Microglobulin
Major histocompatibility complex (MHC) class I and class II
molecules present fragments of peptide antigens to CD8+ or
CD4+ T cells, respectively, and cells lacking such molecules are
unable to interact with immunocompetent T cells (Parnes, 1989).
Presentation of antigenic peptides to CD8+ cells is mediated by
β2-microglobulin, which is non-covalently bound to MHC class I.
Despite being recently observed during hippocampal neurodevel-
opment (Leinster et al., 2013), adult neurons do not constitutively
expressMHC class I (Arthur-Farraj et al., 2012). In contrast, spinal
MNs were shown to display a high constitutive expression of both
MHC class I and β2-microglobulinmRNAs (Thams et al., 2009). A
latest paper describes a strong up-regulation of β2-microglobulin
in MNs during disease progression in the SOD1G93A mice model,
which revealed to be important for the ALS mouse survival (Staats
et al., 2013). Therefore, β2-microglobulin target driven therapies
may be of help in strategies counteracting ALS.
GLIAL CELL RESPONSES
It is believed that non-neuronal cells expressing mSOD1 may
secrete toxic mediators or fail to secrete trophic factors, or both,
resulting in either reduced function or survival of MNs. Indeed,
several SFs were shown to drive axonal degeneration and regional-
speciﬁc microglia activation expressing SODG93A was suggested
to be implicated (Kim et al., 2006b). This calls our attention for the
existence of multiple factors, and MNs and glial cells interplay in
contributing to ALS onset and progression. Microglia activation
and dysfunction have lately been related with the onset, but mostly
with the progression, of several neurodegenerative diseases. Par-
ticularly, in ALS, it has been suggested that besides MNs, also glia
and muscles are implicated in the disease.
Prominent neuroinﬂammation is a pathological hallmark in
human ALS and mouse models of the disease. Gliosis and accu-
mulation of large numbers of activated microglia and astrocytes
can be observed in CNS and in SC areas. Active contributions of
glial cells in ALS pathology have recently been reviewed (Lasiene
and Yamanaka, 2011; Zhao et al., 2013). Conﬂicting results were
published on whether the expression of mSOD1 in astrocytes
and microglia really contributes to the progression of ALS dis-
ease. Some argues against (Yoshii et al., 2011) and others in favor
(for review, see Boillée et al., 2006b). Overall, it will be impor-
tant to identify the molecules released by glia, as well as the ones
secreted by dysfunctional neurons targeting microglia or even
acting retrogradely.
Toll-like receptor activation
Glial cells (astrocytes, microglia, oligodendrocytes, and Schwann
cells), as well as neurons are known to express different members
of the TLR family (Lee et al., 2013b). Increasing evidence indicates
that, in the absence of pathogens, TLR signaling can be activated by
molecules released by the injured tissue, namely the HMGB1 pro-
tein, one of the damage-associated molecular patterns (DAMPs)
molecules (Bianchi and Manfredi, 2009). Recent ﬁndings have
underlined the activation of TLRs and RAGE signaling pathways
in ALS (Casula et al., 2011). TLR2, TLR4, and RAGE expression
was increased in reactive glial cells in both gray (ventral horn)
and white matter in SC. TLR2 was predominantly detected in cells
of the microglia/macrophage lineage, whereas TLR4 and RAGE
were strongly expressed in astrocytes. Activated macrophages
(He et al., 2012) and microglia (personal communication) release
HMBG1 that promotes the secretion of IL-1β and IL-18 further
inducing the necrosis of neighboring neurons and the amount
of extracellular HMBG1, which binds to microglial Mac1 lead-
ing to the activation of nuclear factor-κB (NF-κB) pathway
(Gao et al., 2011) and inﬂammasome (Lu et al., 2013), form-
ing a vicious circle that sustains progressive neurodegeneration
(Figure 1). Recent data have demonstrated that NF-κB activation
in wt microglia causes MN death providing a therapeutic target
for ALS (Frakes et al., 2014).
When evaluating whether extracellular mSOD1 caused a direct
or indirect injury to MNs, it was observed that neurodege-
neration was mediated by microglia and concerted activation of
CD14/TLR pathway involving both TLR2 and TLR4 (Zhao et al.,
2010). In addition, granulocyte macrophage-colony stimulating
factor (GM-CSF), a pleiotropic cytokine predominantly released
by astrocytes that up-regulates TLR4 and CD14 expression in
microglia,may function to exacerbateTLR signaling inALSdisease
(Parajuli et al., 2012). Indeed, when GM-CSF was blocked it was
observed a delayed onset and increased life span in the ALS mice
(Turner and Talbot, 2008). The activation of these pathways may
contribute to the progression of inﬂammation and to a further
injury to MNs.
NG2 Cells, oligodendrocytes, and Schwann cells
Oligodendrocytes in CNS, and Schwann cells in the peripheral
nervous system (PNS), are responsible for the myelin sheaths sur-
rounding neurons which provide electrical insulation essential
for rapid signal conduction. Schwann cells also participate in the
clearance of debris and in guiding the axon after neuron damage
(Ilieva et al., 2009). In the SC injury, reactive gliosis emerges in the
lesion accompanied by the up-regulation of chondroitin sulfate
proteoglycans (CSPGs) in oligodendrocytes and Schwann cells.
Considering the regenerative capacity of NG2 cells, one of the
ﬁrst cells responding to any alteration in CNS environment, it will
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be important to clarify their role inALS since they canbemobilized
to originate cells or to release factors. Nevertheless, NG2 cells
were shown to remain committed to an oligodendrocyte lineage
in both controls and mutant ALS mice, indicating their scarce
participation (Kang et al., 2010). However, increased proliferation
rate of NG2 revealed to mediate an elevated number of early-
born oligodendrocytes that degenerate, resulting in gray matter
demyelination in ALS mice and human CNS (Kang et al., 2013).
Although only a few studies have examined whether oligo-
dendrocytes or myelin sheaths have a role in ALS, the myelin
abnormalities consisting in loss of compact myelin and lamellae
detachment in the SC of pre-symptomatic SOD1 transgenic rats
and aggravated at symptomatic stages (Lasiene and Yamanaka,
2011) suggest that it may be an interesting target for further
study. Biochemical examinations of the myelin structural com-
ponents revealed a decrease in the phospholipid content along
disease progression, as well as in cholesterol (already in the early
presymptomatic stage) and cerebrosides (in theparalyzed animals)
(Niebroj-Dobosz et al., 2007). Degeneration of oligodendrocytes
was observed in human patients and mice models of ALS prior to
the disease (Kim et al., 2013). Cells that were lost were replaced
by newly differentiated oligodendrocyte precursor cells, which,
however, evidenced reduced myelin basic protein. This ﬁnding is
suggestive that they may contribute to MN degeneration in ALS
(Philips et al., 2013). Moreover, these cells evidenced a loss of the
monocarboxylate transporter 1 (MCT1), thus compromising the
supply of lactate to MNs (Table 2).
Little is known about Schwann cell involvement in ALS patho-
logy. Schwann cells are located near the MN axons and are
known to bridge between denervated and reinnervated endplates,
and to guide axonal sprouts (Magrane et al., 2009). Expres-
sion of mSOD1 in perisynaptic Schwann cells was suggested to
interfere with the trophic maintenance of normal or regenera-
ting motor axons (Inoue et al., 2003). In vivo evidence suggests
that glial ﬁbrillary acidic protein (GFAP) up-regulation in the
stressed/proliferating Schwann cells may be the underlying patho-
logical events (Keller et al., 2009). Conversely, different results
were obtained in SOD1G73R mice where elimination of mutant
SOD1G37R from Schwann cells failed to slow disease progres-
sion (Lobsiger et al., 2009). Nevertheless,Wang et al. (2012) found
that knockdown of mSOD1 in Schwann cells of SODG85R trans-
genic mice delayed disease onset and extended survival indicating
that SOD1G85R expression is neurotoxic. These results imply that
diverse mutations confer different outcomes to cell toxicity and,
in the case of Schwann cells, oxidative damage seems to be an
important feature in the context of ALS.
Astrocyte reactivity
Astrocytes are a potential source of both pro- and anti-
inﬂammatory cytokines and are ideally placed in close proximity
to BBB and BSCB, thus translating signals from the periphery
to the CNS. Although not being immune cells, they can also
contribute to the immune response. Astroglial activation, or
astrogliosis, is characterized by hyperplasia, hypertrophy of cell
bodies and cytoplasmic processes, up-regulation of intermediate
ﬁlament proteins, namely GFAP and vimentin, mediating a histo-
logically apparent glial scar at the lesion site in the damaged SC
(Sofroniew, 2009). Reactive astrogliosis in ALS was ﬁrst revealed
in 1990s by increased GFAP staining in the subcortical white mat-
ter (Kushner et al., 1991), and later on similarly observed in the
ventral and dorsal horns of the SC, as well as in the transition
between gray matter and anterior and lateral funiculi, where the
dystrophy of neuritis exists (Schiffer et al., 1996). SC astrocytes
were shown to assume a neurotoxic phenotype in response to
extracellularATP. In SOD1G93A astrocytes this activation ismedi-
ated through P2X7 receptor signaling (Gandelman et al., 2010).
Reactive astrocytes surround degenerating MNs in patients and
transgenic animal models of ALS, and in particular those localized
in the ventral SC of SOD1G93A mice, are a source of nerve growth
factor (NGF) and NO, which are both required for MN apopto-
sis (Table 2) (Pehar et al., 2004). Interestingly, the NO-induced
MN death was shown to be mediated by astrocytes expressing
SOD1 and TDP-43 mutations (Rojas et al., 2014). Ferraiuolo et al.
(2011) have shown that the increase in total NGF is due to the
secreted pro-NGF fraction before cleavage to the mature form,
achieving a twofold increased ratio in the SOD1G93 mice as com-
pared to control conditions. Such ﬁnding may derive from the
increased ALS-associated MMP-9 (Niebroj-Dobosz et al., 2010),
one of the enzymes that degrade mature NGF in the extracellular
space. In this scenario, neuroprotection of MNs could be achieved
by promoting pro-NGF cleavage.
Recently, it was demonstrated that loss of GFAP did not affect
disease onset and marginally shorten the SOD1H46R mice sur-
vival, indicating that GFAP only plays modulatory effects (Yoshii
et al., 2011), at least in this mice. On the contrary, astroglio-
sis was observed in the SOD1G93A mice in either symptomatic
or presymptomatic phase, preceding microglial activation (Yang
et al., 2011). Indeed, depending on the ALS animal model used,
astrocyte activation was observed to occur earlier or later and to
be rather complex, increasing and decreasing in waves at dif-
ferent times throughout the disease (for review, see Evans et al.,
2013). Despite no differences in the astrocyte number, increased
GFAP labeling in the ventral horn of lumbar SC from SOD1G93A
mice was observed before MN loss (Gerber et al., 2012). Astro-
cytes derived from such mice evidenced to uptake glutamate less
efﬁciently and showed a reduced trophic response to activation,
deﬁciently protecting MNs (Benkler et al., 2013). Attesting this
low astrocyte efﬁciency, the mainly expressed astroglial S100B
protein was found to be decreased in CSF (Sussmuth et al.,
2003) and serum (Otto et al., 1998) from ALS patients. Inter-
estingly, exposure of primary cultures of astrocytes from ALS
patients to CSF evidenced to enhance GFAP and S100B expres-
sion (Shobha et al., 2010). Similarly to neurons, astrocytes have
demonstrated constitutive and regulated expressionof FKN,which
may control the migration and function of the microglia (Sun-
nemark et al., 2005). Additional contribution of astrocytes to
MN death involves the release of ROS mediated by mitochon-
drial dysfunction and of D-serine that is a co-activator of the
NMDARs, thus exacerbating glutamate excitotoxicity, among
other factors as indicated in Table 2 and reviewed in Valori et al.
(2014).
A recent publication has characterized a speciﬁc astrocytic phe-
notype (aberrant astrocytes) obtained fromprimary SC cultures of
SOD1G93A symptomatic rats (Diaz-Amarilla et al., 2011). These
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aberrant astrocytes isolated on the basis of marked proliferative
capacity and lack of replicative senescence, lack GLT-1 and the
NG2 marker and were shown to release toxic factors accounting
for a MN hostile environment. This speciﬁc astrocyte phenotype
expressing increased S100B and connexin-43 (Cx-43) is abundant
in the symptomatic phase of the disease and seems to be located
close to MNs, representing a new potential target for delaying ALS
progression.
Data in postmortem tissues of ALS patients revealed changes
in the morphology of astrocytes together with elevated GFAP
and aldehyde dehydrogenase family 1, member L1 (ALDH1L1)
(Philips and Robberecht, 2011), corroborating ﬁndings in ani-
mal models of ALS. Indeed, mSOD1 gene excision from microglia
and selective reduction in astrocytes signiﬁcantly slowed disease
progression (Yamanaka et al., 2008b). However, there is still some
controversy on whether astrogliosis is detrimental or beneﬁcial,
what surely will depend from spectrum intensity and toxicity
potential of the aberrant phenotype.
Microglia activation
Microglia are the immune resident cells of the CNS with both
a supporting role to neurons and astrocytes, and immuno-
logical properties with either neuroprotective or neurotoxic
potential. Though microglia activation was indicated to pre-
cede astrocyte reactivity (Alexianu et al., 2001), reduced neu-
roprotective behavior of mSOD1 microglia in a resting-state
(Sargsyan et al., 2011), and at the disease end-stage (Nikode-
mova et al., 2013) was documented. If conﬁrmed, boosting of
microglia with stimulatory factors may reveal to be clinically
useful.
In a recent paper, Roberts et al. (2013) veriﬁed that incuba-
tion of microglia with aggregated SOD1 ﬁrst drives its location at
the membrane level, and later within the cell. Moreover, super-
natants of these SOD1 activated microglia caused a signiﬁcant
decrease in MN viability, which was not related with tumor necro-
sis factor-α (TNF-α) secretion, NO, or superoxide anion radical.
The toxic factors involved are currently unknown, although it was
shown that expression of mSOD1 increases TNF-α secretion (Liu
et al., 2009), which may induce neurotoxicity by increasing the
glutamate release by microglia in an autocrine manner (Takeuchi
et al., 2006). Therefore, a very early stage of the disease may rely
in this link between protein aggregation and microglial activa-
tion. Indeed, neurotoxic potential of mutant microglia in MN
degeneration in ALS is a very well documented issue: (1) mSOD1
acting on microglia is required to cause the disease (Clement et al.,
2003); (2) limiting mutant damage to microglia slows progres-
sion (Boillée et al., 2006b); replacement of mSOD1 microglia for
wt microglia delays disease and prolongs mice survival (Lee et al.,
2012).
Microgliosis at sites of MN injury is a neuropathological hall-
mark of ALS and recent therapeutic interventions are looking into
factors capable of skewing microglia neurotoxic potential into
a neuroprotective phenotype. However, a trophic role for acti-
vated microglia has been suggested at early stages of the disease
(for review, see Lewis et al., 2012). In the SOD1G93A mice, it
was observed a decrease in microglia number in the entire SC
at the pre-symptomatic age (Gerber et al., 2012). The authors
identiﬁed two diverse microglia subpopulations (low and high
Iba1 expression cells), suggesting a distinct microglia involve-
ment at pre- and early-symptomatic ALS stages. Interestingly,
microglia heterogeneity observed between cervical and lumbar
SC regions in ALS mice may derive from different environmen-
tal speciﬁcities determined by local MN/astrocyte/lymphocyte
disposition and activation (Beers et al., 2011b). While cortical
microglia appear unaffected by the disease, additional studies
evidenced an increased microglial number in the lumbar SC
at symptom onset, and neither the typical inﬂammatory nor
the anti-inﬂammatory phenotypes were identiﬁed at end-stage
(Nikodemova et al., 2013). In addition, elevated TNF-α gene
expression and immunoreactivity were observed in lumbar SC of
mSOD1mice and relatedwith invadingmicroglia (Yoshihara et al.,
2002). Early microglia activation in ALS may be further explored
in vivo by positron emission tomography (PET). The possibilities
of PET suggest its valuable contribution to monitor the progres-
sion of the disease and the efﬁcacy of the therapy in use (Corcia
et al., 2012).
Context-dependent neuroprotective and neurotoxic properties.
An important neuroprotective role of microglia is phagocyto-
sis. Following signaling by neuronal FKN, milk-fat globule EGF
factor-8 protein (MFG-E8, SED1) is up-regulated and serve as
a bridge via speciﬁc integrins between apoptotic neurons and
microglia (Figure 1) (Leonardi-Essmann et al., 2005). The authors
hypothesize that MFG-E8 is assembled on the surface of exo-
somes and apoptotic neurons so microglia can recognize their
target cells. MFG-E8 seems to be essential for microglia engulf-
ment and removal of the dying neurons. An interesting concept
is that inﬂammatory microglia can also phagocyte viable neurons
(Fricker et al., 2012a) through MFG-E8 mediation (Fricker et al.,
2012b) accounting for a reduced number of neurons. Phagocytic
ability may, however, be lost if the cell is continuously stressed by
a neurotoxic stimulus.
Our recent data with the neurotoxic unconjugated bilirubin
have evidenced that following the phagocytic ability at eliminating
cell debris microglia changes to a more inﬂammatory phenotype
(Silva et al., 2010) and even to a senescent-like cell morphology
and death if the duration of exposure is prolonged. However,
microglia behavior in the presence of unconjugated bilirubin is
modulated by the presence of both astrocytes and neurons (Silva
et al., 2011). Also to consider is that during the inﬂammatory
phenotype, microglia may intervene in the glutamate homeosta-
sis, but may also contribute to neurite degeneration through
the release of NO (Silva et al., 2012). Interestingly, microglia
phagocytic features were shown to occur early in ALS disease.
Microglia were revealed to aggregate, proliferate, and phago-
cyte in the lumbar SC of pre-symptomatic mutant SOD1H46R
transgenic mice (Sanagi et al., 2010). However, in other studies
microglia have shown to contribute to MN death (Dibaj et al.,
2011; Brettschneider et al., 2012) and to decrease in number
within disease progression (Butovsky et al., 2012), thus contribu-
ting to the disease propagation. By using in vivo imaging by
two-photon laser-scanning microscopy and axonal transection, it
was observed different phases of microglia-mediated inﬂamma-
tion in the ALS mice model. Indeed, a ﬁrst phase (preclinical)
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with highly reactive microglia was followed by another (clini-
cal stage) with morphologically transformed microglia presenting
reduced surveillance activity and reactivity (Dibaj et al., 2011).
Regional, temporal, and immune environmental differences may
contribute to changes in microglia phenotypes and response
heterogeneity, thus requiring differentiated immunomodulatory
or even combinatory therapeutic approaches along ALS disease
progression.
Microglia phenotypes. Activation of microglia may be observed
through the up-regulation of CD11b, Iba1, and CD68 markers.
Primary microglia differ from other blood macrophages in the
expression of CD11b/CD45low/high and CD68low/high (for review,
see Hinze and Stolzing, 2011), although not speciﬁc for microglia
in a pathologic brain (Matsumoto et al., 2007). These cells show
a round morphology with an enlarged cell body and smaller and
thicker processes in the resting/quiescent state (M0; Figure 2).
When activated in response to an insult or injury, microglia are
capable of acquiring diverse and complex phenotypes, allowing
them to participate in the cytotoxic response, immune regulation,
and injury resolution. Microglia may then favor the entrance of
inﬂammatory T cells with which the cells seem to interact. Recent
work have classiﬁed and characterized M1 and M2 phenotypes
(Table 2) (for review, see Evans et al., 2013). The ﬁrst is cytotoxic,
characterized by the release of proinﬂammatory cytokines and
inﬂuenced by T helper cell type 1 (Th1) that release GM-CSF and
interferon-γ (IFN-γ), triggering M1 proliferation. Cytotoxic M1
markers include IL-1β, IL-6, TNF-α, iNOS, COX2, and CX3CL1,
and known inducers are the TLR4 agonist LPS and IFN-γ (Chhor
et al., 2013).
The M2, promoted by the cytokines IL-4 and IL-13 released by
Th2, contribute to neuroprotection once they also secrete anti-
inﬂammatory cytokines, such as IL-4 and IL-10, and growth
factors such as insulin-like growth factor 1 (IGF-1). Indeed, IL-4
was shown to protect MNs from the injury produced by LPS-
activated microglia (Zhao et al., 2006). Thus, M2 polarization
may be desirable, although excessive or prolonged M2 pola-
rization may become prejudicial in allowing unwanted ﬁbrotic
responses and scarring, not facilitating axonal growth. However,
there are three M2 phenotypes: the M2a or alternate activation
repair/regeneration/remodeling phenotype, theM2b immunoreg-
ulatory and the M2c acquired-deactivating (Figure 2). Reliable
markers for M2a stimulated by IL-4 and IL-13 are high IL-1
receptor antagonist (IL-1Ra) and high arginase (Arg1). M2b is
stimulated by immune complexes, TLR agonists and IL-1R lig-
ands. Useful markers are IL-1Ra and SOCS3. Characterization of
M2c stimulated by IL-10, transforming growth factor-β (TGF-β)
and glucocorticoids is obtained through the increased levels of
anti-inﬂammatory cytokines (IL-10, TGF-β), low levels of pro-
inﬂammatory cytokines and enhanced IL-4Rα, Arg1, SOCS3, and
CD206 (David and Kroner, 2011; Wilcock, 2012; Chhor et al.,
2013). While LPS, IL-1β, TNF-α, and IFN-γ lead to cytotoxic
M1 and immunomodulatory M2b activation states, IL-4 mainly
triggers M2a phenotype (Chhor et al., 2013).
Therefore, balance between M1 and M2 phenotypes may be a
desirable therapeutic goal. Interestingly, mSOD1 microglia iso-
lated from ALS mice at disease onset showed higher levels of
Ym1, CD163, and brain-derived neurotrophic factor (BDNF)
(M2 markers) and lower levels of Nox2 mRNA (M1 marker)
as compared to the end-stage disease (Liao et al., 2012). Inte-
restingly, when co-cultured with wt MNs the ﬁrst microglia
phenotype exerted neuroprotection while the M1 phenotype was
neurotoxic, supporting the pathoprogression-related changes in
microglia. We may probably consider that microglia display the
M2 phenotype at an early stage of the disease switching to the
M1 phenotype during the late rapid phase (reviewed in Zhao
et al., 2013). However, we should also consider that microglia
may become functionally impaired at the end-stage, as recently
observed in the SOD1G93A SC microglia (Nikodemova et al.,
2013). Different roles of microglia depending on the neurolog-
ical disease context was recently suggested by Chiu et al. (2013)
based on the observation by FACS-transcriptome comparisons
that SOD1G93A microglia show a unique phenotype that dif-
fers from M1 or M2 macrophages, and from activation with LPS.
Robust up-regulation of MMP-12, IGF-1 and osteopontin were
pointed as hallmarks. Transcriptomic technology has been car-
ried out to examine the gene expression changes of ALS tissue
as compared to controls (reviewed in Heath et al., 2013) and in
the future may provide insights into the microglia phenotype
proﬁling prior to disease onset and along ALS progression to
assist in the development of new treatments for ALS at different
stages.
Inﬂammatory microRNA proﬁling. MicroRNAs (miRNAs),
small, non-coding RNAs, have been recently pointed to mediate
cell-to-cell communication (Xu et al., 2013). Inﬂammatory phe-
notypes are miR-155, miR-21, miR-146a/b, and miR-124 (Quinn
and O’Neill, 2011). Recent studies demonstrated the miR-124
involvement in promoting microglia quiescence by skewing their
polarization from an M1 to an M2 phenotype (Willemen et al.,
2012) and that miR-155 together with miR-124 are likely to be
directly related to M1 and M2 phenotypes, respectively (Cardoso
et al., 2012; Ponomarev et al., 2013). Up-regulation of miR-155
is induced by TNF-α and Il-1β (Pottier et al., 2009), as well as
by HMGB1 through the activation of the TLR2/MyD88/miR-
155 pathway (Wen et al., 2013), while it is down-regulated by
TGF-β (Pottier et al., 2009). Increase of miR-146a expression
was shown to occur in the aged mice (Rodier and Campisi,
2011), as well as after LPS stimulation (Jiang et al., 2012), and
is related with the microglia phagocytic potential (Saba et al.,
2012). Moreover, up-regulation of miR-21 in murine models
of SC injury was pointed as a modulator of the pro-reactive
effects of inﬂammatory signaling cascades (Nieto-Diaz et al.,
2014). Dysregulation of miRNAs expression was lately found
in the SC of ALS patients and in microglia isolated from the
hSOD1G93A mice. Promising candidates that were found to
be altered in patients were miR-146a∗, miR-524-5p, and miR-
582-3p (Campos-Melo et al., 2013), while those up-regulated in
the mice model were miR-155, miR-146b, miR-22, miR-365,
and miR-125b (Parisi et al., 2013), which need to be further
investigated for their relevance as ALS biomarkers and therapeu-
tic targets. Actually, it was recently discovered that inhibition
of miR-155 prolongs survival in the mSOD1 mice (Koval et al.,
2013).
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FIGURE 2 | Altered cross-talk between glial cells and motor
neurons (MNs) in ALS disease. Many studies report the intervention
of mutated superoxide dismutase-1 (SOD1)-expressing non-neuronal cells
in the pathogenesis of the disease. In case of injury, astrocytes
become activated in a process called astrogliosis, characterized by the
up-regulation of intermediate ﬁlament glial ﬁbrillary acidic protein (GFAP)
and increased release of toxic products into the extracellular media,
such as pro-inﬂammatory cytokines [tumor necrosis factor-α (TNF-α),
interleukin-1β (IL-1β)] oxidative stressors [reactive oxygen species (ROS),
nitric oxide (NO)], as well as glutamate and ATP mediated by the
receptor P2X7. In addition, astrocytes also evidence a reduced
expression of the glutamate transporter GLT-1, which additionally
contribute to neuronal excitotoxicity. However, reactive astrocytes
up-regulate nerve growth factor (NGF), which can modulate neuronal
survival. Disorganization and destruction of the myelin sheath with a
progressive loss of phospholipids and cholesterol is also observed.
Moreover, oligodendrocytes also evidence a loss of the of the
monocarboxylate transporter 1 (MCT1), thus compromising the energy
supply to MNs. On the other hand, increased mutated SOD1
expression in Schwann cells may have intricate ways contributing to
slow ALS progression. When mutated SOD1 accumulates within
microglia, there is a pattern of activation. Microglia acquire different
activation phenotypes (M0, M1, M2a, M2b, M2c, and
dystrophic/senescent) and, consequently, produce a diversity of
substances that may be either beneﬁcial [insulin-like growth factor 1
(IGF-1), transforming growth factor-β (TGF-β), brain-derived neurotrophic
factor (BDNF), and nerve growth factor (NGF)] or toxic (glutamate, ROS,
NO) to other cells. Phagocytosis is mediated by the release of milk
factor globule-8 (MFG-E8) from microglia M1 and M2c phenotypes that
recognizes phosphatidylserine (PS) in apoptotic neurons. Reliable markers
for M2a are high IL-1 receptor antagonist (IL-1Ra) and high arginase, for
M2b are IL-10, TNF-α, IL-6, and IL-1β, for M2c are TGF-β and IL-10 and
for M1 are TNF-α, IL-6, and IL-1β, increased inducible nitric oxide
synthase (iNOS) and toll-like receptors (TLR)2 and 4.
Autotaxin. Autotaxin (ATX) is a secreted lysophospholipaseD that
converts lysophosphatidylcholine (LPC) to lysophosphatidic acid
(LPA), a phospholipid growth factor that activates several trans-
duction pathways, and is involved in migration, proliferation, and
survival of various cells (Mori et al., 2011; Furukawa et al., 2013).
LPA acts as an autocrine and/or paracrine signaling molecule
mediating a broad range of intracellular signaling cascades, espe-
cially the RHOA pathway (reviewed in Willier et al., 2011). LPA
receptors are expressed by astrocytes, oligodendrocytes, and
microglia (Lorenzl et al., 2006; Shi et al., 2010a; He et al., 2013).
Data suggest that ATX levels increase within reactive astrocytes
following neurotrauma (Savaskan et al., 2007), but other studies
have obtained a down-regulation instead (Shi et al., 2010b). Most
fascinating, it was observed that overexpression of ATX inhibits
microglial activation and protects the cell against oxidative stress
(Awada et al., 2012). Thus, reduced expression of ATX in microglia
may contribute to a sustainedneuroinﬂammation condition. Since
ATX is also amotility driver that stimulates cell invasion (Sau et al.,
2007; Hoelzinger et al., 2008; Magrane and Manfredi, 2009) it can
be involved in microglia migration, a property not exploited till
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now. Although ATX is considered an inﬂammatory mediator we
were not able to ﬁnd studies demonstrating its relevance or not in
ALS.
NEUROVASCULAR CHANGES
BBB and BSCB are dynamic and complex interfaces between the
blood and the CNS. Endothelial cells and tight junctional com-
plexes physically limit solute exchanges between the blood and
the brain. These cells together with pericytes, astrocytes, neurons,
microglia, and oligodendrocytes and the basement membrane
form the neurovascular unit (for review, see Cardoso et al., 2010;
Sá-Pereira et al., 2012). The interaction between all these com-
ponents provides a sustainable environment for neural function
while restricting permeability and transport. Alterations in bar-
rier properties and dynamics were observed in transgenic SOD1
rats (Andjus et al., 2009; Nicaise et al., 2009). In particular, it was
noticed a reduction of endothelial tight junctions (Zhong et al.,
2008), together with the disruption of the neurovascular unit
and up-regulation of MMP-9 (Miyazaki et al., 2011) prior to MN
degeneration. MMP-9 activation was observed in blood vessel-
like structures and microglia. Increased microvascular microglia,
expressing CX3CR1 and weakly labeling Iba1, were detected in
the SCs from the ALS mice model and suggested to have a bone
marrow origin (Lewis et al., 2009). In addition, it was recently
demonstrated that SC microglia in the mSOD1 mice promote the
recruitment of inﬂammatory monocytes into the CNS well before
the onset of the disease, triggering microglia apoptosis (Table 2)
(Butovsky et al., 2012). Actually, the BSCB has been shown to
be disrupted in different mSOD1 mice before MN degeneration,
thus favoring blood monocytes inﬁltration (Barbeito et al., 2010).
To that it may account the 54% reduction in pericytes at the BSCB
level in patients with ALS (Winkler et al., 2013). In fact, some
authors considerALS as aneurovascular disease (Garbuzova-Davis
et al., 2012) with evidence indicating impairment of all neurovas-
cular unit components, including the BBB and the BSCB in both
ALS patients and animal models. Disruption of BBB and BSCB
was observed in theG93Amice by electronmicroscopy in places of
MNdegeneration at both early and late disease stages (Garbuzova-
Davis et al., 2007). The damage of barriers besides allowing the
entrance of T lymphocytes, such as CD4+ (helper/inducer) and
CD8+ (cytotoxic) into the brain parenchyma, may also permit the
entrance of harmful substances that will contribute to disrupt neu-
ronal homeostasis and accelerate MN degeneration. The impact of
microvascular damage in ALS pathology is a novel and promising
research topic in that interactions with glia may determine neuro-
protective or cytotoxic cell phenotypes with consequences on MN
survival.
INFLAMMATORY COMPONENTS IN ALS AND PATHOLOGICAL
CELL–CELL COMMUNICATION
Communication between neurons and microglia is essential for
maintaining homeostasis in the CNS and altered cross-talk is
implicated in the pathogenesis of ALS and other MN diseases
(Appel et al., 2011). Dysregulated neuron–neuron signaling and
neuron–microglia cross-talk in ALS, and other neurodegenera-
tive diseases, may derive from: (i) secretion of toxic mediators
or fail to secrete trophic factors, or both, resulting in reduced
function and survival of MNs; (ii) SFs released by neurons and
their action on microglia receptors; (iii) changes in direct cellular
interactions.
Reduced expression of trophic factors such as BDNF, ﬁbroblast
growth factor 2 (FGF2), and IGF-1 was found in the SC of the
newborn rat after intrathecal administration of CSF from ALS
patients (Deepa et al., 2011). To note, that the release of mSOD1
was shown to trigger microgliosis and neuronal death (Urushi-
tani et al., 2006) and increased levels of ROS/RNS, mainly of NO,
were shown to play a critical role in the earliest stages of neuronal
dysfunction in ALS (Drechsel et al., 2012). NO mainly produced
by glia through the activation of iNOS can react with superoxide
producing the potent oxidant peroxynitrite (Beckman et al., 1990),
which mediates apoptosis or necrosis, depending on the concen-
tration (Bonfoco et al., 1995). Peroxynitrite also induces toxic glial
phenotypes further propagating oxidative damage and cellular
dysfunction. Interestingly, the same concentrations of NO may
either promote the survival of MNs healthy conditions or induce
apoptosis and glia reactivity when in the presence of stressors. Up-
regulation of neuronal NO synthase (nNOS) was shown to occur
in MNs before iNOS in either pre-symptomatic ALS animal mod-
els or in patients and tobe associatedwithMN loss (Moreno-Lopez
et al., 2011; Drechsel et al., 2012).
Activated microglia and astrocytes amplify the initial damage
to the MNs by activating AP-1 and NF-κB through production
of proinﬂammatory cytokines and apoptosis-triggering molecules
such as TNF-α and Fas ligand (FASL). TNF-α and IL-1β exert neu-
rotoxic effects in vitro, but deletion of the individual genes seems
to not affect the course of the disease. In addition, dying MNs
release ATP that can further activate glia through the puriner-
gic receptor P2X7 expressed by both microglia and astrocytes
(Figure 2) (Gandelman et al., 2010; Glass et al., 2010). Classi-
cal microglia activation results in upregulation of MHC class II
proteins that are involved in presentation of antigens to T lym-
phocytes. Microglia activation is mediated by the release of SFs
and/or expression of surface receptors by neurons and astrocytes,
such as CX3CL1, CD200, and CCL21. Microglia also express a
diverse set of pattern recognition receptors (PRRs) for pathogen-
associated molecular patterns (PAMPs) and endogenous ligands
derived from injury that include TLRs and inﬂammasome. In
addition, emerging evidence suggests that members of the nuclear
receptor (NR) family of transcription factors, many of which are
ligand-dependent, control the activation of microglia under phys-
iological and pathological conditions (for review, see Saijo et al.,
2013).
Neuroinﬂammation involves the activation and proliferation
of microglia and the inﬁltration of T cells into the brain and SC.
In these conditions, astrocytes and microglia release IL-1β, TNF-
α, and IL-6 (Figure 2). Cytokines can then up-regulate oxidative
stress by NO and superoxide (O2-) generation (for review, see
Philips and Robberecht, 2011). Repair and limitation of the dam-
age is promoted by the release of trophic and anti-inﬂammatory
factors. Deleterious microglia M1 and benign M2 phenotypes
are inﬂuenced by astrocytes and T cell subsets. In ALS, it is still
currently unknown the precise function of microglia and astro-
cytes and how they mediate neuroinﬂammation and contribute
to the pathology. Identiﬁcation of the factors driving microglia
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phenotype and consequent functional changes, once known, may
advance our knowledge on their role and on ways to modulate
these cells. In addition, it will be important to clarify whether
inﬂammation contributes to ALS pathogenesis or in opposite is a
protective response, and if different individual immune responses
to the disease are also implicated, so that immunomodulatory
therapies can be pursued.
MICROGLIA–T CELL CROSS-TALK
Evidence for autoimmunity in ALS was proposed in 1990s (for
review, see Appel et al., 1993). Inﬂammation is not a resultant
from MN degeneration since it regulates the balance between neu-
roprotection and neurotoxicity (Henkel et al., 2009). Initially, the
diverse populations and phenotypes of CD4+ T cells that cross-
talk with microglia can slow disease progression, but later they
may contribute to the acceleration of the disease. The inﬂamma-
tory process involves inﬁltration of T cell subpopulations at sites of
neuronal injury in the brain parenchyma. T cellsmay damageMNs
by cell–cell contact or cytokine secretion through the activation of
microglia (Holmoy, 2008). CD8+ cytotoxic T cells and natural
killer T (NKT) cells were found signiﬁcantly increased in patients
with ALS, while regulatory T (Treg) cells were decreased (Rent-
zos et al., 2012). It was suggested that CD4+ T cells may trigger
oxidative phosphorylation in microglia and CD8+ may stimulate
phagocytosis accordingly to data obtained by FACS-transcriptome
comparisons in cells isolated from the SC of SOD1G93A mice
(Chiu et al., 2013).
The naive T cells, or Th0 cells, expand and differentiate into
at least four functionally distinct subsets upon stimulation: Th1,
Th2, Treg, and Th17 cells. Th1 cells secret IFN-γ and turn rest-
ing microglia into M1 phenotype; in contrast Th2 and Treg cells
release IL-4 which induces activation of resting microglia into M2
phenotype (for review, see Lewis et al., 2012). Th1 and Th17 are
CD4+ T cells that produce proinﬂammatory cytokines, causing
damage while CD4+CD25high T lymphocytes (Treg) suppress Th1
cell effector function (Dittel, 2008).
Interestingly, it was demonstrated that mSOD1 mice lacking
CD4+ T cells evidence a faster disease progression and decreased
microglia reactivity and as so, future therapeutic interventions
should consider the beneﬁts that T cells may have (Beers et al.,
2008; Chiu et al., 2008; Zhao et al., 2013). Compromise of Treg
lymphocytes with disease progression diminishes the secretion
of IL-4 and fails in suppressing the toxic properties of microglia
(Beers et al., 2011a). Indeed, mSOD1 Treg suppress immune to-
xicity by inhibitingmicroglial activation, CD4+CD25− (T effector
cells) proliferation, and the accompanying cytotoxicity, thus pro-
viding MN protection in ALS (Zhao et al., 2012). As disease
progresses, the supportive Treg/Th2/M2 changes to an injuri-
ous Th1/M1 response triggering increased TNF-α secretion that
was shown to induce the dysfunction of Tregs (Zhao et al., 2013).
Therefore, elevation of Tregs in patients with ALS may trigger a
longer life expectancy.
MN–ASTROCYTE CROSS-TALK
It was before considered that the mutant protein was the responsi-
ble for the disease onset in MNs with microglia and astrocytes only
determining disease progression and extent. However, expression
of mSOD1 in microglia and astrocytes is now being related with
the disease onset and early stage disease, while healthy SOD1 in
those cells was shown to delay ALS progression.
Several studies evidenced the demise of MNs in the pres-
ence of astrocytes harboring SOD1 mutations (Yamanaka et al.,
2008b), attesting the non-cell-autonomous pathology in ALS, i.e.,
degeneration of MNs requires mSOD1 expression in other cells
additionally to neurons. This ﬁnding was similarly obtained for
astrocytes derived from ALS patients, which have shown to cause
MN death (Haidet-Phillips et al., 2011). Deregulation between
astrocytes and MNs communication seems to involve TGF-β sig-
naling pathways (Phatnani et al., 2013) and miR-124a mediated
regulation (Morel et al., 2013). Evidence for the role of miRNAs
in MN diseases is substantiated by the relevance that the proteins
TDP-43 and FUS/TLS, responsible for the processing of miRNAs,
RNA maturation and splicing (Kiernan et al., 2011), have recently
acquired in ALS (Lagier-Tourenne and Cleveland, 2009; Haramati
et al., 2010). A major challenge would be to establish circulating
miRNAs as particularly accessible biomarkers to monitor ALS.
Activated astrocytes (see Astrocyte Reactivity for more details)
may also interfere with MNs function due to the reduced secretion
of trophic factors such as BDNF, glial cell line-derived neu-
rotrophic factor (GDNF) and vascular endothelial growth factor
(VEGF), but this is not a clariﬁed issue yet (for review, see Evans
et al., 2013).
REGULATION OF ASTROCYTE–MICROGLIA INTERCONNECTIVITY
ACTIVATION
Both in vitro and in vivo experiments have shown that astro-
cytes and microglia containing mSOD1 exert deleterious effects
on MNs, by releasing proinﬂammatory factors (Phani et al., 2012).
Microglia may respond earlier than astrocytes to injury and stress
by ﬁrst activating NF-κB and mitogen-activated protein kinase
(MAPK) signaling pathways, thus leading to a faster release of
TNF-α and IL-1β (Brites, 2012). In that way one may believe that
the activation of microglia precedes the reactivity of astrocytes
and depends from the factors and cytokines that microglia release.
Curiously, TNF-α and IL-1β released from activated microglia
were reported to produce an inhibitory effect on Cx-43 expres-
sion, the main constitutive protein of gap junctions. Therefore,
blockage of communication between astrocytes by the activated
microglia can contribute to decrease the neuroprotective role
of astrocytes (Meme et al., 2006). When considering the p25-
mediated neuroinﬂammation, astrogliosis was shown to precede
microglia activation, and apparently mediate the production of
LPC,which as a chemoattractant for T cells may recruit peripheral
cells into the brain (Sundaram et al., 2012). Recently, it was shown
that astrocytes depend on functionalmicroglia for response to LPS
and to TLR2, 3, and 4 ligation. In their absence, astrocytes did not
respond to TLR4 ligation and only weakly responded to TLR2 and
3 ligation (Holm et al., 2012). Thus, activation of astrocytes may
be modulated by the proinﬂammatory cytokines released from
microglia in an attempt to diminish the extent of excitotoxicity
(Tilleux et al., 2007), but they can modulate microglia activation,
as well (Welser and Milner, 2012). Which cells between microglia
and astrocytes are ﬁrst activated by the aggregatedmSOD1 is a very
controversial issue since different studies have obtained diverse
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proﬁles of glial activation in ALS models along disease progres-
sion. Some studies point out that microglia activation precede
astrocyte reactivity (Alexianu et al., 2001). Others that astrogliosis
is initiated in the symptomatic phase, while prominent microglio-
sis is only evident later at the moribund phase (Yang et al., 2011).
However, since a close interaction/communication of both cells
occurs in ALS, a better understanding of the beneﬁts and risks
of astrocyte and microglia activation in ALS will help to deter-
mine whether therapeutic strategies should envisage enhancing or
impairing the actions of glial cells in ALS.
MN–MICROGLIA SIGNALING
Communication between MNs and microglia is essential for
maintaining local homeostasis during both physiological and
inﬂammatory conditions. Neuroprotective signaling from MN to
microglia involve FKN and CD200, as previously mentioned. In
addition, microglia “calming” effects during neuroinﬂammation
are mediated through ATX (Awada et al., 2012). Insights into the
complex intercellular perturbations and inﬂuence of alarming and
calming factors underlying neurodegeneration will enhance our
efforts toward target-driven directed therapeutic strategies in ALS.
CX3CR1 deﬁciency
The neuroprotective/neurotoxic role of CX3CL1/CX3CR1 signal-
ing is still a matter of debate once it seems to depend upon the
CNS insult (for review, see Desforges et al., 2012). Deletion of
CX3CR1 in a transgenic model of ALS mice was shown to extend
neuronal cell loss, suggesting that CX3CL1/CX3CR1 signaling
limits microglial toxicity in ALS (Cardona et al., 2006). Interest-
ingly, it was also shown that treatment with LPS down-regulated
the expression of CX3CR1, thus suppressing the functional
response to FKN (Boddeke et al., 1999) and potentiating LPS
neurotoxic effects (Zujovic et al., 2000). Accordingly, in ALS, the
disruption of CX3CL1/CX3CR1 signaling evidenced to promote
neurodegeneration following LPS administration (Cardona et al.,
2006).
Cathepsin S inﬂuence
Although it has been proposed that cathepsins compensate
for each other because of their overlapping substrate speci-
ﬁcities, there is increasing evidence that disturbance of the
normal balance and extralysosomal localization of cathepsins
contribute to age-related diseases (for review, see Nakanishi,
2003). CatS that is a lysosomal/endosomal cysteine protease
that degrades extracellular matrix proteins, even at neutral pH,
was shown to be increasingly expressed by microglia upon LPS
surcharge (Petanceska et al., 1996). However, some authors indi-
cate that a further challenge with ATP is required to observe
CatS release (Clark and Malcangio, 2012). This protease is
preferentially expressed by antigen-presenting cells, including
microglia.
Microglial CatS seems to be responsible for the liberation of
neuronal FKN (Figure 1), which via the speciﬁc receptor CX3CR1
in microglia activate p38 MAPK pathway leading to the release of
mediators that interact with neurons (Clark et al., 2007). Several
inhibitors have been tried to regulate the immune modulatory
effects of CatS (Clark and Malcangio, 2012) and a shift from a
Th1/Th17 type response to a Th2 type of response was obtained
(Baugh et al., 2011).
The up-regulation of cathepsins appears as a general trans-
criptional event in ALS (Gonzalez de Aguilar et al., 2008; Offen
et al., 2009; Boutahar et al., 2011). However, reference to CatS and
microglia activation was not until now indicated in the context of
ALS. Therefore, if CX3CL1/CX3CR1 demonstrates to have a role
in any stage of ALS progression, inhibition of CatS may constitute
a therapeutic approach for ALS.
Exosomes and disease spread
Exosomes are secretory vesicles deriving from late endosomes
and multivesicular bodies that mediate neuron–glia communi-
cation, have 50–100 nm in size and carry speciﬁc protein and RNA
cargo (Fitzner et al., 2011; Fruhbeis et al., 2012; El Andaloussi
et al., 2013). Exosomes contain both miRNAs and mRNAs that
may be delivered and be functional in another cell (Valadi et al.,
2007). Selectivity for miRNA incorporation into exosomes is pro-
posed based on the fact that some are exclusive in exosomes
derived from immature dendritic cells while others only exist
in those from mature dendritic cells (Stoorvogel, 2012). Indeed,
exosomes and miRNAs have been found to participate in cellu-
lar senescence and contribute to aging (Xu and Tahara, 2013).
In addition senescent cells produce high levels of exosomes thus
interacting and inducing the senescence of neighboring cells. As
so, exosomal miRNAs might become useful biomarkers of disease.
Recently, it was suggested that exosomes may be important can-
didates to deliver siRNA (El Andaloussi et al., 2013) and speciﬁc
drugs, based on the perceived advantages of nanoparticle size and
non-cytotoxicity (Sun et al., 2013), thus constituting a therapeutic
platform.
Microglia was shown to internalize oligodendroglial exosomes,
thus participating in the degradation of oligodendroglial mem-
brane (Fitzner et al., 2011). However, microglia also release
exosomes (Potolicchio et al., 2005; Hooper et al., 2012), which
generate IL-1β to the extracellular environment propagating
inﬂammation (Turola et al., 2012). Increased exosome discharge
by microglia was observed after stimulation with α-synuclein and
such activated exosomes revealed an increased membrane content
in TNF-α (Chang et al., 2013). Interestingly, it was shown that
mouse MN-like NSC-34 cells overexpressing hSOD1G93A secrete
SOD1 via exosomes probably accounting to cell–cell-mediated
mutant toxicity in ALS pathogenesis (Gomes et al., 2007). There-
fore, exosomes from microglia may spread pathogenic factors,
such as SOD1 and promote inﬂammation while inﬂuencing neu-
ronal survival (Chang et al., 2013). In line with this, a latest study
reports that cell-to-cell transmission of SOD1 misfolding is medi-
ated by two non-exclusive mechanisms: through the release of
protein aggregates that are taken up by macropinocytosis or via
exosomes secreted from living cells (Grad et al., 2014).
CHALLENGES TO NERVE REGENERATION IN ALS
Reconstruction of neural network implies the restoration of tis-
sue architecture and cell functionality. Cell replacement-based
repair strategies have been tested both in vitro and in vivo and
a major challenge resides in maintaining the cell function when
transplanted to a broken parenchyma homeostasis. Confront with
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excessive neuroinﬂammation and cell senescence may compro-
mise the success of the strategy. In particular, reactive astrocytes
exacerbate inﬂammation and by forming glial scars impede rege-
nerating axons from traversing the lesions, while myelin debris
prevent axon growth and microglia lose the ability to migrate,
phagocyte or sustain inﬂammation from spread. Therefore, the
rewiring of the CNS to foster a permissive environment for neu-
roregeneration is the key to a successful functional integration and
repair (Xu et al., 2011; Kim et al., 2012).
CELL SENESCENCE
Redox changes within neurons (Olivieri et al., 2001), ER stress
condition (Di Virgilio, 2000), and mitochondria dysfunction
(Konnecke and Bechmann, 2013) are accelerated by aging and
are emerging as common features relevant to the pathogenesis of
neurological disorders, including ALS. Actually, the variation in
SOD1 activity in aging ALS patients, when compared to younger
ones, point to an increased oxidative misbalance vulnerability
(Fiszman et al., 1999). Nevertheless, it was recently indicated that
the ALS incidence decline in the elderly (Schoser and Blottner,
1999; Demestre et al., 2005), suggesting that the disease is not
merely the result of aging. However, markers of senescence were
found increased in satellite cells from ALS muscle biopsies sug-
gesting a vulnerability to muscle atrophy (Gottschall and Deb,
1996). In addition, autophagic dysfunction and mitochondrial
DNA damage in the CNS are prominently found in microglia
with aging and may lead to a defective turnover of mitochondria
and accumulation of hypergenerated ROS (reviewed in Nakan-
ishi and Wu, 2009). Interestingly, dysfunctional and senescent
microglia may even release compounds that inhibit neuronal
autophagy (Alirezaei et al., 2008) and neurogenesis (reviewed in
Wong, 2013). Given the important and necessary functions of
microglia in the CNS homeostasis it is of major relevance to
understand the multiple stage-related microglia phenotypes in
ALS, including the increased vulnerability to a senescent cell with
the disease progression, as observed in other neurodegenerative
and age-related CNS disorders (Luo et al., 2010; Kaplan et al.,
2014).
Microglia degeneration
Recent data obtained in the mSOD1 mouse model suggest a domi-
nant neuroinﬂammatory response in the CNS, with a reactive
microglia in preclinical stages that turns into an irresponsive cell
during disease progression, and a degenerative process in the
PNS (Dibaj et al., 2011). Earlier studies evidenced that mutated
SOD1 microglia have an age-dependent cytotoxic potential which
reveals upon a stimulatory effect (Weydt et al., 2004). Interestingly,
extracellular SOD1G93A mediates the activation of CD14–TLR2
pathway with the consequent release of TNF-α and IL-1β, thus
propagating the proinﬂammatory stimuli (Bowerman et al., 2013).
However, since immunosuppressive strategies have not proven
consistent efﬁcacy (Appel et al., 1993, 2011; Baugh et al., 2011),
one may believe that microglia function may change along disease
progression with consequent differential effects on MNs. Late data
evidenced that SC microglia proliferate and that TNF-α mRNA
expression decreases during disease progression in SOD1G93A
rats (Nikodemova et al., 2013). Indeed, microglia revealed to not
be polarized to M1 or M2 phenotypes at any disease stage and
CNS region evaluated. In addition, SC microglia evidenced to
be irresponsive to experimental systemic inﬂammation at ALS
end-stage. Diminished glial neuroprotection by senescent and/or
dysfunctional microglia has been suggested to play a role in neu-
rodegenerative diseases, mainly in the late stage (Streit, 2006). In
such circumstances the aged microglia evidenced a “dystrophic”
morphology with the loss of ﬁnely branched cytoplasmic pro-
cesses, cytoplasmic beading/spheroid formation, and cytoplasmic
fragmentation (cytorrhexis; Figure 2) (Streit et al., 2004). Such
severe abnormalities in microglia, including cell fusion (multi-
nucleated giant cells) at the symptomatic stage and cytorrhexis
at the end stage are indicative of microglial aberrant activation
and degeneration, respectively, and were observed in SOD1G93A
transgenic rats (Fendrick et al., 2007). Although prevalent in older
human subjects this dystrophic cells may also in rare instances be
observed in the young brain (Luo and Chen, 2012). Pathogenic
miRNAs, such as miR-155, miR-146a, and miR-124 in microglia
may be associated with the acquisition of a senescent pheno-
type (Saba et al., 2012; Ponomarev et al., 2013). We recently
observed that aged-cultured microglia exhibit lower phagocytic
ability and higher expression levels of miR-146a than younger cells
(Caldeira et al., 2013). Whether these ﬁndings are related with a
dysfunctional microglia at ALS end-stages deserve to be further
investigated.
Demyelination progression
Although new oligodendrocytes were observed in the SC of
SOD1G93A mice, they do not fully maturate, resulting in pro-
gressive demyelination and accelerated disease (Liu et al., 2002).
The authors also found similarmyelination defects in postmortem
samples taken from SC and motor cortex from ALS patients.
Actually, there are many potent inhibitors of axonal regenera-
tion in the injured CNS including myelin-associated proteins,
ﬁbrinogen, and axonal guidance molecules, where epidermal
growth factor receptor (EGFR) and eukaryotic ribosome bio-
genesis protein 1 (Erb1) may have a special role in reducing
the effects of multiple inhibitors of axonal regeneration (Arthur-
Farraj et al., 2012; Leinster et al., 2013). However, the role of
EGFR on the protection of MN synapses and survival exten-
sion in SOD1G93A mice is still a matter of debate; hence, it was
reported that EGFR inhibitors failed to extend ALS mouse sur-
vival although inﬂuencing disease progression (Le Pichon et al.,
2013).
Another important point to be considered is the decrease
in the phagocytic clearance by the dysfunctional microglia that
results in the accumulation of myelin debris, leading to oligo-
dendrocyte differentiation arrest and decreased recruitment of
oligodendrocyte precursor cells (Walter and Neumann, 2009).
Activated microglia were also shown to attenuate the prolifera-
tion of the oligodendrocyte precursor cells, thus concurring for
demyelinationprogression (Taylor et al., 2010), and reinforcing the
recovery of healthy microglia as a potential therapeutic target in
ALS. Indeed, studies on the global gene expression during demyeli-
nation and remyelination by microarray analysis reinforced that
the primary function of microglia is the tolerance induction and
support to regeneration (Olah et al., 2012).
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CELL REPLACEMENT THERAPY
Cell replacement therapy has been suggested as a promising stra-
tegy for MN disease. The use of combined strategies to restore
both the healthy state of MNs and glial cells, such as microglia,
and their correct cross-talk to face persistent neurotoxic insults
may even provide better beneﬁts for this devastating disease.
Mesenchymal stem cells (MSCs) isolated from the bone mar-
row of ALS patients did not show morphological or functional
differences from those obtained from donors and seem to be use-
ful for cell-based therapy for ALS patients (Hadass et al., 2013). In
a few well-monitored ALS patients the autologous transplantation
of such MSCs into the SC evidenced to be well tolerated and to
promote some clinical improvement (Min et al., 2012).
Another proposed strategy is the olfactory ensheathing cell
(OEC) transplantation that although evidencing to slow the rate
of ALS progression in a short period (Inoue et al., 2003) and to
improve pulmonary function (Guegan et al., 2001) has been a
matter of debate. Indeed, prominent glial and inﬂammatory reac-
tion around the brain delivery track was observed in postmortem
samples (Reyes et al., 2010).
Efﬁcacy of transplantation-based astrocyte replacement was
also evidenced as a promising therapy for slowing focal MN
loss associated with ALS while also reducing microgliosis in the
hSOD1G93A rodents (Lepore et al., 2008). Effectsmay derive from
the release of growth factors that are decreased in ALS and already
evidenced to increase mSOD1 mice survival (Kaspar et al., 2003;
Park et al., 2009). However, limited efﬁcacy was obtained in a later
study (Lepore et al., 2011). The use of induced pluripotent stem
cell (iPSC) technologies may allow in the future the autologous
cell transplantation in ALS patients, including MNs (Papadeas
and Maragakis, 2009).
More recently, depletion of microglia cells expressing mSOD1
with clodronate liposomes and subsequent transplantation with
bone marrow cells (BMCs) expressing wtSOD1 was shown to trig-
ger microglia replacement and to slow ALS disease progression in
the SOD1G93A mice model (Lee et al., 2012). The method seems
to afford better therapeutic effects than the one by Ohnishi et al.
(2009) using BMCs transplantation since microglia renewal is bet-
ter achieved by tissue-resident microglia rather than by BMCs
(Davoust et al., 2008). Overall, the mechanisms and functional
implications of microglia replacement require further elucidation,
inasmuch because myeloid-derived inﬁltrating cells (monocyte-
derived macrophages) revealed to be functionally distinct from
the resident microglia assisting them (Jung and Schwartz, 2012;
London et al., 2013). Clearly, additional research is required to
address these issues and contribute to develop strategies able to
stop, or at least delay, ALS progression.
CONCLUSION
Amyotrophic lateral sclerosis is a fatal neurodegenerative disor-
der with limited identiﬁed targets, biomarkers, and therapeutic
options. Therefore, a better comprehension of the underlying
molecular mechanisms is necessary to develop novel etiological
therapeutic strategies. Multiple studies suggest that a complex
pathological interplay between MNs and glial cells, involving neu-
roinﬂammation and microglia physiopathological changes drive
the performance of these glial cells before theALSonset andduring
disease progression till late and end stages. In this context, we here
summarized the growing body of evidence supporting the key role
of microglia in the deregulated motor-neuron interconnectivity
and in the dreadful chain of events leading to MN degeneration in
ALS. As such, insights into the complex intercellular perturbations
underlying ALS disease and centered on microglia phenotypic
changes, and associated detrimental functions, will help on our
efforts to develop effective therapeutic approaches for recovering
adequate microglia function in initiation and progression phases
of ALS. In conclusion, the role of microglia in keeping brain
homeostasis leads to consider that healthy microglia may be used
to replace the senescent or irresponsive cell. In addition, dysfunc-
tional microglia may be differently modulated, either directly or
indirectly, to be transformed in a less reactive cell to challenges
in excessive and chronic neuroinﬂammation, or alternatively reju-
venated to enhance their capacity to ﬁght the insult and improve
disease outcomes. Considerably more research is necessary to real-
ize the feasibility and usefulness of such strategies before their
potential in clinic can be realized.
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